**Phase I**

- Disruption of DOHH interaction with its substrate, deoxyhypusinyl-eIF5A
- Inhibition of eIF5A maturation
- Suppression of HIV-1 promoter-dependent transcript initiation
- Inhibition of HIV RNA accumulation
- Reduction of HIV gene expression

**Phase II**

- Loss of HIV control over the fate of infected cells: apoptosis of infected cells